|Other Names||PAS domain-containing protein 1, Cancer/testis antigen 63, CT63, OX-TES-1, PASD1|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Functions as a suppressor of the biological clock that drives the daily circadian rhythms of cells throughout the body (PubMed:25936801). Acts as a nuclear repressor of the CLOCK- ARNTL/BMAL1 heterodimer-mediated transcriptional activation of the core clock components (PubMed:25936801). Inhibits circadian clock function in cancer cells, when overexpressed (PubMed:25936801).|
|Cellular Location||Isoform 1: Nucleus. Note=Associates preferentially at the periphery of the nucleus with heterochromatin (PubMed:25936801).|
|Tissue Location||Testis-specific (PubMed:25936801). Expressed in a broad range of cancer cells, including melanoma, lung cancer, and breast cancer (at protein level). Testis-specific (PubMed:15162151). Found in histologically normal tissues from patients with uterus, lung and small intestine cancers. Widespread expression seen in solid tumors and diffuse large B-cell lymphoma (DLBCL)-derived cell lines. Isoform 2 is expressed in all DLBCL- derived cell lines, while isoform 1 is preferentially expressed in cell lines derived from non-germinal center DLBCL (PubMed:15162151).|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a protein that is thought to function asa transcription factor. The protein is a cancer-associated antigenthat can stimulate autologous T-cell responses, and it is thereforeconsidered to be a potential immunotherapeutic target for thetreatment of various hematopoietic malignancies, including diffuselarge B-cell lymphoma.
Ghafouri-Fard, S., et al. Br. J. Dermatol. 162(4):772-779(2010)Ait-Tahar, K., et al. Br. J. Haematol. 146(4):396-407(2009)Sahota, S.S., et al. Blood 108(12):3953-3955(2006)Cooper, C.D., et al. Leukemia 20(12):2172-2174(2006)Guinn, B.A., et al. Biochem. Biophys. Res. Commun. 335(4):1293-1304(2005)
If you have any additional inquiries please email technical services at email@example.com.